Literature DB >> 24969610

[New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].

B Gallwitz1, S Nitschmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24969610     DOI： 10.1007/s00108-014-3523-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  5 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies.

Authors:  Thomas Forst; Markolf Hanefeld; Stephan Jacob; Guido Moeser; Gero Schwenk; Andreas Pfützner; Axel Haupt
Journal:  Diab Vasc Dis Res       Date:  2013-01-04       Impact factor: 3.291

4.  Basal insulin and cardiovascular and other outcomes in dysglycemia.

Authors:  Hertzel C Gerstein; Jackie Bosch; Gilles R Dagenais; Rafael Díaz; Hyejung Jung; Aldo P Maggioni; Janice Pogue; Jeffrey Probstfield; Ambady Ramachandran; Matthew C Riddle; Lars E Rydén; Salim Yusuf
Journal:  N Engl J Med       Date:  2012-06-11       Impact factor: 91.245

Review 5.  Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.

Authors:  Julio Rosenstock; Nikolaus Marx; Steven E Kahn; Bernard Zinman; John J Kastelein; John M Lachin; Erich Bluhmki; Sanjay Patel; Odd-Erik Johansen; Hans-Jürgen Woerle
Journal:  Diab Vasc Dis Res       Date:  2013-02-28       Impact factor: 3.291
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.